Also known as: IGF-1
Genetic doping is no longer theoretical; 92% of athletes underwent anti-doping testing before the Winter Olympics 2026. Experts propose genomic passports, noting no confirmed cases but black-market availability of plasmid-based EPO genes.
The FDA accepted Camurus' NDA resubmission for Oclaiz in acromegaly, setting a December 2026 PDUFA date. The filing follows a June 2026 Complete Response Letter related to third-party manufacturing, with no safety or efficacy issues. Oclaiz is a once-monthly subcutaneous octreotide already approved in the EU as Oczyesa.
Acromegaly patients face persistent symptoms including fatigue, joint pain, headaches, and brain fog despite biochemical control. Treatment burden and financial barriers remain significant, particularly in sub-Saharan Africa where diagnostic tools and therapies are often inaccessible.
Loyal's LOY-002, a daily pill for senior dogs, has cleared two of three FDA requirements for conditional approval. If approved, it would be the first drug for lifespan extension in any species, potentially reaching vets in late 2026.
